US government seeks to negotiate Medicare prices of high-cost medicines

3 February 2015
usa-white-house

The Obama Administration wants to win the authority to negotiate over the prices of specialty drugs for recipients of Medicare, the federal government program that providers health coverage to the elderly, according to US media reports.

President Barack Obama on Monday called for government to use its buying power to squeeze drug companies for lower prices. The request came as part of the $1.08 trillion budget submission for the Health and Human Services Department for fiscal 2016, which would give the HHS the ability to negotiate drug prices for biologics and other medications in Medicare Part D.

"I think it's something we believe will help with the issue of drug prices," HHS Secretary Sylvia Burwell said during a briefing with reporters, reported by The Hill. Secretary Burwell added that the Administration would work with Congress to establish that authority.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical